Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin

Rhea-AI Summary

Defence Therapeutics (OTCQB:DTCFF) featured Dr. Amie Phinney, Director of Strategy & Business Advisor, in an interview on Money Talk Radio discussing the company's Accum® drug delivery platform. The interview highlighted how Accum® technology enhances Antibody-Drug Conjugates (ADCs) delivery by improving payload efficiency and reducing toxic side effects.

Dr. Phinney explained that Accum® provides "laser-guided precision" for cancer cell targeting, potentially enabling ADCs to transition from second-line to first-line therapy by addressing dose-limiting toxicity issues. The company's strategy includes worldwide IP protection and plans to partner with existing ADC developers while manufacturing Accum® for various therapeutic applications.

Positive

• Accum® platform demonstrates improved efficiency in drug delivery to cancer cells
• Technology could enable ADCs to become first-line therapy options
• Company has strong IP protection strategy worldwide
• Multiple potential revenue streams through partnerships and manufacturing

Negative

• No immediate revenue generation mentioned
• Still requires partnerships for commercialization

Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to share the interview of Dr. Amie Phinney, Defence's director, strategy & business advisor, with Ellis Martin on Money Talk Radio.

To listen to the interview, please visit:
https://youtu.be/HhhfU2exrqw

What you'll learn in this interview:

How Dr. Phinney's career path from the University of Guelph to the University of Basel, and into global pharma leadership, shaped her unique perspective on the intersection of science and business.

Why Accum^® is a game-changer for ADC delivery, giving drugs "laser-guided precision" inside cancer cells, improving payload efficiency, and reducing toxic side effects.

The analogy: instead of sending 100 soldiers to target a cancer cell with only 2 reaching the nucleus, Accum^® allows 10 to go in with 2 succeeding—achieving the same effect with far less collateral toxicity.

Why ADCs, though powerful, are often relegated to second-line therapy due to dose-limiting toxicity—and how Accum^® may enable their use as first-line therapies.

Defence's strategy to protect its strong IP portfolio worldwide, including a "picket fence" approach covering multiple aspects of the delivery platform.

Near-term revenue outlook: how Defence plans to partner with existing ADC developers, manufacture Accum^®, and expand its applications to novel therapies.

Why this matters:

Antibody-drug conjugates are among the most effective anti-cancer drugs available, but their broader use has been limited by toxicity. Defence Therapeutics' Accum^® platform could change the paradigm—enabling safer, more efficient, and more widely adopted precision oncology treatments.

This interview highlights how Defence is moving from scientific discovery to impactful innovation, leveraging Accum^® to transform the biotech landscape. With partnerships, IP protection, and strategic execution, the Company is positioning itself as a leader in next-generation drug delivery.

About The Ellis Martin Report:

The Ellis Martin Report (TEMR) and Money Talk Radio feature interviews with industry leaders in mining, biotech, energy, and technology. The program is globally syndicated through multiple financial platforms and streaming services.

About Defence:

Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM^® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.

For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267546

FAQ

What is Defence Therapeutics' Accum® technology and how does it improve cancer treatment?

Accum® is a drug delivery platform that provides 'laser-guided precision' for cancer cell targeting, improving payload efficiency and reducing toxic side effects in Antibody-Drug Conjugates (ADCs).

How does DTCFF's Accum® platform reduce toxicity in cancer treatments?

Accum® reduces toxicity by requiring fewer drug molecules to achieve the same therapeutic effect, using an efficient targeting system that delivers more payload to the cancer cell nucleus.

What are Defence Therapeutics' revenue plans for the Accum® platform?

Defence plans to generate revenue through partnerships with existing ADC developers, manufacturing of Accum®, and expanding its applications to novel therapies.

What is Defence Therapeutics' strategy for protecting their Accum® technology?

Defence employs a 'picket fence' approach to IP protection, covering multiple aspects of their delivery platform worldwide.

How could Accum® change the current use of Antibody-Drug Conjugates in cancer treatment?

Accum® could potentially enable ADCs to be used as first-line therapies instead of second-line treatments by addressing their dose-limiting toxicity issues.